Table 1.

Demographic, clinical, and laboratory characteristics of the patients with SS.

Features of Patients with SS1st MSG Biopsy2nd MSG Biopsy
General
  Age, yrs; median (quartiles)50.5 (36–55)54.5 (42–59)
  Duration of sicca symptoms, yrs; median (quartiles)3 (1–7)
Clinical
  Arthralgias, n (%)11 (39.3)11 (39.3)
  Arthritis, n (%)2 (7.1)3 (10.7)
  Salivary gland enlargement, n (%)12 (42.9)16 (57.1)
  Raynaud’s phenomenon, n (%)9 (32.1)9 (32.1)
  Parenchymal organ involvement, n (%)0 (0.0)1 (3.6)
    Lung involvement, n (%)0 (0.0)0 (0.0)
    Renal involvement, n (%)0 (0.0)1 (3.6)
    Liver involvement, n (%)0 (0.0)0 (0.0)
  Indicative of vasculitic involvement, n (%)4 (14.3)6 (21.4)
    Palpable purpura, n (%)4 (14.3)6 (21.4)
    Vasculitis, n (%)0 (0.0)1 (3.6)
    Peripheral neuropathy, n (%)0 (0.0)0 (0.0)
  Lymphoma, n (%)0 (0.0)5 (17.9)
Laboratory
  Leukopenia, n (%)5 (17.9)5 (17.9)
  Hyper-gammaglobulinemia, n (%)9 (32.1)9 (32.1)
  C4 levels, median (quartiles)18.7 (12.2–25.1)21.8 (11.4–39.9)
  Anti-Ro(SSA) and/or La(SSB) positive, n (%)22 (78.6)22 (78.6)
    Anti-Ro(SSA) positive, n (%)22 (78.6)22 (78.6)
    Anti-La(SSB) positive, n (%)12 (42.9)12 (42.9)
  Cryoglobulinemia, n (%)4 (14.3)5 (17.9)
Therapy
  Pilocarpine-hydrochloride, n (%)0 (0.0)7 (25.0)
  Hydroxychloroquine, n (%)2 (7.1)5 (17.9)
  Pilocarpine-hydroxychloroquine, n (%)1 (3.6)3 (10.7)
  Corticosteroids, n (%)3 (10.7)2 (7.1)
  Pilocarpine-corticosteroids, n (%)0 (0.0)3 (10.7)
  Hydroxychloroquine-corticosteroids, n (%)1 (3.6)0 (0.0)
  Pilocarpine-corticosteroids-methotrexate, n (%)0 (0.0)1 (3.6)
  B cell depletion0 (0.0)0 (0.0)
  None, n (%)21 (75.0)7 (25.0)